Truqap can be a kinase inhibitor that works by blocking pathways that help the most cancers cells endure and mature, so cuts down cancer development. Truqap is from a class of medicines referred to as an AKT inhibitor. Truqap obtained FDA acceptance on November 17, 2023, just after favourable effect